Sensus Healthcare (NASDAQ: SRTS): A Strong Start to 2024 with Impressive Financial Growth and Strategic Innovations

Sensus Healthcare, Inc. (NASDAQ: SRTS), a leader in non-invasive and minimally invasive treatments for both oncological and non-oncological conditions, has reported a substantial leap in its financial and operational performance for the first quarter of 2024. The company’s recent financial disclosures and strategic moves have captured significant attention, demonstrating its robust growth trajectory and innovation in medical technology.

Financial Highlights and Achievements

Sensus Healthcare’s financial results for the first quarter ended March 31, 2024, were nothing short of impressive. The company’s revenues skyrocketed to $10.7 million, marking a 214% increase compared to $3.4 million in the same quarter of the previous year. This surge was primarily driven by a significant uptick in the sales of its superficial radiotherapy (SRT and IG-SRT) units, with 26 systems shipped compared to just 10 in the prior year.

The company also turned its financial situation around dramatically, posting a net income of $2.3 million, or $0.14 per diluted share, a substantial recovery from a net loss of $1.9 million, or $0.12 per share, in the first quarter of 2023. Additionally, Sensus ended the quarter robustly with $14.7 million in cash and cash equivalents and no debt, positioning it well for continued expansion and development.

Strategic Developments and Market Expansion

Beyond financials, Sensus Healthcare has been strategically advancing its market presence and product offerings. The company launched the “Fair Deal Agreement” recurring revenue program for the SRT-100 Vision™ (IG-SRT), enhancing customer engagement and satisfaction. This program has been well-received, as evidenced by the company’s strong presence and positive feedback at major trade conferences such as the Winter Clinical, South Beach Symposium, and the American Academy of Dermatology Annual Meeting.

The company also celebrated the issuance of a U.S. patent for its SRT-100 Vision System (IG-SRT), which underscores its commitment to innovation. The technology, which integrates radiation therapy with high-frequency ultrasound, enhances treatment planning capabilities, demonstrating Sensus’s leadership in cutting-edge medical technology.

Global Reach and Future Prospects

Sensus Healthcare’s international footprint is expanding, with notable achievements including the first sale of the SRT-100 Vision System (IG-SRT) in Asia to Far Eastern Memorial Hospital in Taiwan and its first commercial sale of an SRT-100 for veterinary use outside the U.S. These milestones not only underscore the versatility and global appeal of Sensus’s products but also highlight the company’s ability to penetrate diverse markets.

Management’s Vision

Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, expressed confidence in the company’s trajectory, noting the significant momentum in business as more customers recognize the benefits of SRT as a non-invasive and efficacious modality to treat conditions like non-melanoma skin cancer. “Our goal is to make SRT the standard of care for treating non-melanoma skin cancer and keloids,” stated Sardano, underscoring a vision of growth and innovation.


Sensus Healthcare’s first quarter of 2024 has set a positive tone for the year, with strong financial results, strategic advancements, and expanding global reach. As the company continues to innovate and execute its strategic plans, the outlook for Sensus remains promising, with significant potential for continued growth and market penetration in the fields of oncology and beyond.